Based on these findings, we explored the impact of PPM1D inhibition using Ewing sarcoma and neuroblastoma cell line models, because both tumors are often TP53 WT and clinically treated with DNA damaging agents including chemotherapy and radiation. The gene discussed is TP53; the disease is neuroblastoma.